NCT05918211招募中3 期
Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL-2)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 436
- 试验地点
- 40
- 主要终点
- Change in Exercise Capacity
研究概览
简要总结
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
详细描述
This study is a 26 week, prospective, multicenter, randomized, double-blinded, placebo-controlled safety and efficacy study of udenafil vs. placebo in adolescent subjects who have had the Fontan procedure. The primary efficacy endpoint will be change from baseline at 26 weeks in peak minute oxygen consumption (VO2 mL/kg/min) as measured by maximal cardiopulmonary exercise test (CPET) reading laboratory who will be blinded to treatment allocation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Active and matching placebo tablets will be identical in appearance.
入排标准
- 年龄范围
- 12 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females with Fontan physiology who are 12 to less than 19 years of age at enrollment.
- •Participant consent or parental/guardian consent and participant assent.
- •Participant fluency in primary language of country in which study is being conducted.
- •Current antiplatelet or anticoagulant therapy.
排除标准
- •Height < 132 cm.
- •Weight < 40 kg.
- •Hospitalization for acute decompensated heart failure within the last 12 months.
- •Current intravenous inotropic drugs.
- •Undergoing evaluation for heart transplantation or listed for transplantation.
- •Diagnosis of active protein losing enteropathy or plastic bronchitis within the last 3 years, or a history of liver cirrhosis.
- •Known Fontan baffle obstruction, branch pulmonary artery stenosis, or pulmonary vein stenosis resulting in a mean gradient of > 4 mmHg between the regions proximal and distal to the obstruction as measured by either catheterization or echocardiography, obtained prior to screening for the trial.
- •Single lung physiology with greater than 80% flow to one lung.
- •Failure to achieve maximal exertion (defined as RER < 1.10) on screening/baseline exercise test.
- •Peak minute oxygen consumption (VO2) less than 45% or ≥ 80% of predicated for age and gender at enrollment.
- •Severe ventricular dysfunction assessed qualitatively by clinical echocardiography within 6 months prior to enrollment.
- •Severe valvar regurgitation, ventricular outflow obstruction, or severe aortic arch obstruction assessed by clinical echocardiography within six months prior to enrollment.
- •History of significant renal (serum creatinine > 2.0), hepatic (serum AST and/or ALT > 3 times upper limit of normal), gastrointestinal or biliary disorders that could impair absorption, metabolism or excretion of orally administered medications.
- •Inability to complete exercise testing at baseline screening.
- •Subjects with a pacemaker whose heart rate at peak exercise is controlled by the extrinsic pacemaker as opposed to a native atrial rhythm.
- •History of PDE-5 inhibitor use within 12 months prior to enrollment. (Treatment is defined as chronic therapy as opposed to a single dose.)
- •History of any other medication for treatment of pulmonary hypertension within 3 months before study onset.
- •Known intolerance to oral udenafil.
- •Frequent use of medications or other substances that inhibit or induce CYP3A
- •Current use of alpha-blockers or nitrates.
- •Ongoing or planned participation in another research protocol that would either prevent successful completion of planned study testing or invalidate its results.
- •Noncardiac medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would invalidate its results.
- •Cardiac care, ongoing or planned, at a non-study center that would impede study completion.
- •For females: Pregnancy at the time of screening, pregnancy planned before study completion, or refusal to use an acceptable method of contraception for study duration if sexually active.
- •Unable to abstain or limit intake of grapefruit juice and grapefruit containing drinks during the duration of the trial.
- •Refusal to provide written informed consent/assent.
- •In the opinion of the investigator, the subject is likely to be non-compliant with the study protocol.
- •History of clinically significant thromboembolic event, in the option of the site Principal Investigator, that may put the subject at increased risk of a subsequent event while participating in the study.
- •Coronavirus disease 2019 (COVID-19) vaccination or symptoms of COVID-19 infection within 7 days of Visit
- •Not taking antiplatelet or anticoagulant therapy.
研究组 & 干预措施
Drug
Experimental
Approximately 218 subjects dosed with udenafil will be enrolled at approximately 30 sites.
干预措施: Udenafil (Drug)
Placebo
Experimental
Approximately 218 subjects dosed with matching placebo will be enrolled at approximately 30 sites.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Exercise Capacity
时间窗: Baseline to 26 Weeks
The change in exercise capacity (as measured by maximal VO2 at maximum exercise effort) from baseline to 26 weeks (or study completion)
次要结局
- Change in VO2 at the ventilatory anaerobic threshold (VAT)(Baseline to 26 weeks)
- Change in Enhanced Liver Fibrosis (ELF) Score(Baseline to 26 weeks)
- Work rate (watts) at ventilatory anaerobic threshold (VAT)(Baseline to 26 weeks)
- Change in ventilatory efficiency (VE/VCO2) at ventilatory anaerobic threshold(Baseline to 26 weeks)
研究者
研究点 (40)
Loading locations...
相似试验
已完成
3 期
Fontan Udenafil Exercise Longitudinal Assessment TrialSingle Ventricle Heart DiseaseNCT02741115Mezzion Pharma Co. Ltd400
终止
3 期
Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart FailureSystolic Heart FailureNCT01646515Seoul National University Hospital41
撤回
2 期
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile DysfunctionErectile DysfunctionBenign Prostatic HyperplasiaNCT01967251Takeda
已完成
3 期
Treatment of Erectile Dysfunction - Long Term Safety and EfficacyErectile DysfunctionNCT01065012Warner Chilcott1,027
已完成
1 期
Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican AdultsPhosphodiesterase 5 InhibitorErectile DysfunctionNCT01967264Takeda83